<DOC>
	<DOC>NCT02442466</DOC>
	<brief_summary>Intra-lesion administration of an Endothelin Receptor B inhibitor (BQ-788) or vehicle was preformed in 5 melanoma patients to have a preliminary analysis of safety, dose, duration and relevance of results observed in pre-clinical studies to the human disease.</brief_summary>
	<brief_title>Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>BQ 788</mesh_term>
	<criteria>Written Informed consent Histologically confirmed melanoma Disease stage III or IV At least 2 injectable and surgically removable cutaneous metastasis Age &gt; 18 years Clinically stable medical condition Primary ocular melanoma Symptomatic intracranial melanoma History of severe neurological, cardiovascular, renal, hepatic, endocrinological, respiratory, bone marrow, autoimmune or infectious (HIV) disease Pregnancy or lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>